ONTARIO, Canada, Nov. 9, 2018 /PRNewswire-iReach/ -- Methapharm is pleased to announce that it has participated in a PrivatePlacement of a Convertible Debenture of Triumvira Immunologics Inc.
Methapharm is a privately held specialty pharmaceutical company that focuses on the acquisition, licensing, and promotion of healthcare products
About Triumvira Immunologics
Triumvira Immunologics, Inc. is an immuno-oncology company, developing a novel platform for engineering T cells to attack both liquid and solid tumors. Triumvira's proprietary T Cell-Antigen Coupler (TAC) co-opts the natural T Cell receptor biology and functions. This approach operates through the native T cell receptor, in turn optimizing selectivity and signaling, and has demonstrated superiority over CAR-T in pre-clinical studies. Led by a management team with decades of drug development expertise, Triumvira's pipeline includes multiple oncology trials slated to enter the clinic in 2019.
Media Contact: Chris Calenti, Methapharm Inc., 5197513602, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Methapharm Inc.
Subscribe to our Free Newsletters!